Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score

Morten Würtz; Kevin Kris Warnakula Olesen; Martin Bødtker Mortensen; John W Eikelboom; Moman Aladdin Mohammad; David Erlinge; Steen Dalby Kristensen; Michael Maeng

doi:10.1093/eurheartj/ehab785

Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score

Morten Würtz, Kevin Kris Warnakula Olesen, Martin Bødtker Mortensen, John W Eikelboom, Moman Aladdin Mohammad, David Erlinge, Steen Dalby Kristensen, Michael Maeng

Department of Clinical Medicine - The Department of Cardiological Medicine B

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

Abstract

Aims According to the 2019 European Society of Cardiology (ESC) guidelines on chronic coronary syndromes (CCS), adding a P2Y12 inhibitor or rivaroxaban to aspirin should be considered in high-risk patients. We estimated the proportion of patients eligible for treatment with the ESC criteria and examined if a recently validated risk score (CHADS-P(2)A(2)RC) could improve risk prediction. Methods and results We included 61 338 CCS patients undergoing first-time coronary angiography in Western Denmark (2003-16) and classified them according to the ESC criteria and the CHADS-P(2)A(2)RC score. The ESC criteria identified 33.9% as high risk, 53.3% as moderate risk, and 12.8% as low risk. The CHADS-P(2)A(2)RC score identified 24.9% as high risk (>= 4 points), 48.1% as moderate risk (2-3 points), and 27.0% as low risk (

Original language	English
Journal	European Heart Journal
Volume	43
Issue	10
Pages (from-to)	996-1004
Number of pages	10
ISSN	0195-668X
DOIs	https://doi.org/10.1093/eurheartj/ehab785
Publication status	Published - Mar 2022

Keywords

Aspirin
Chronic coronary syndrome
Coronary artery disease
Myocardial infarction
Platelet inhibitors
Rivaroxaban

Access to Document

10.1093/eurheartj/ehab785

Cite this

@article{f3e4d2ce91ee4e55a37845e25b7868d4,

title = "Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score",

abstract = "Aims According to the 2019 European Society of Cardiology (ESC) guidelines on chronic coronary syndromes (CCS), adding a P2Y12 inhibitor or rivaroxaban to aspirin should be considered in high-risk patients. We estimated the proportion of patients eligible for treatment with the ESC criteria and examined if a recently validated risk score (CHADS-P(2)A(2)RC) could improve risk prediction. Methods and results We included 61 338 CCS patients undergoing first-time coronary angiography in Western Denmark (2003-16) and classified them according to the ESC criteria and the CHADS-P(2)A(2)RC score. The ESC criteria identified 33.9% as high risk, 53.3% as moderate risk, and 12.8% as low risk. The CHADS-P(2)A(2)RC score identified 24.9% as high risk (>= 4 points), 48.1% as moderate risk (2-3 points), and 27.0% as low risk (",

keywords = "Aspirin, Chronic coronary syndrome, Coronary artery disease, Myocardial infarction, Platelet inhibitors, Rivaroxaban",

author = "Morten W{\"u}rtz and Olesen, {Kevin Kris Warnakula} and Mortensen, {Martin B{\o}dtker} and Eikelboom, {John W} and Mohammad, {Moman Aladdin} and David Erlinge and Kristensen, {Steen Dalby} and Michael Maeng",

year = "2022",

month = mar,

doi = "10.1093/eurheartj/ehab785",

language = "English",

volume = "43",

pages = "996--1004",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "10",

}

Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score. / Würtz, Morten ; Olesen, Kevin Kris Warnakula ; Mortensen, Martin Bødtker et al.
In: European Heart Journal, Vol. 43, No. 10, 03.2022, p. 996-1004.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

TY - JOUR

T1 - Dual antithrombotic treatment in chronic coronary syndrome

T2 - European Society of Cardiology criteria vs. CHADS-P2A2RC score

AU - Würtz, Morten

AU - Olesen, Kevin Kris Warnakula

AU - Mortensen, Martin Bødtker

AU - Eikelboom, John W

AU - Mohammad, Moman Aladdin

AU - Erlinge, David

AU - Kristensen, Steen Dalby

AU - Maeng, Michael

PY - 2022/3

Y1 - 2022/3

N2 - Aims According to the 2019 European Society of Cardiology (ESC) guidelines on chronic coronary syndromes (CCS), adding a P2Y12 inhibitor or rivaroxaban to aspirin should be considered in high-risk patients. We estimated the proportion of patients eligible for treatment with the ESC criteria and examined if a recently validated risk score (CHADS-P(2)A(2)RC) could improve risk prediction. Methods and results We included 61 338 CCS patients undergoing first-time coronary angiography in Western Denmark (2003-16) and classified them according to the ESC criteria and the CHADS-P(2)A(2)RC score. The ESC criteria identified 33.9% as high risk, 53.3% as moderate risk, and 12.8% as low risk. The CHADS-P(2)A(2)RC score identified 24.9% as high risk (>= 4 points), 48.1% as moderate risk (2-3 points), and 27.0% as low risk (

AB - Aims According to the 2019 European Society of Cardiology (ESC) guidelines on chronic coronary syndromes (CCS), adding a P2Y12 inhibitor or rivaroxaban to aspirin should be considered in high-risk patients. We estimated the proportion of patients eligible for treatment with the ESC criteria and examined if a recently validated risk score (CHADS-P(2)A(2)RC) could improve risk prediction. Methods and results We included 61 338 CCS patients undergoing first-time coronary angiography in Western Denmark (2003-16) and classified them according to the ESC criteria and the CHADS-P(2)A(2)RC score. The ESC criteria identified 33.9% as high risk, 53.3% as moderate risk, and 12.8% as low risk. The CHADS-P(2)A(2)RC score identified 24.9% as high risk (>= 4 points), 48.1% as moderate risk (2-3 points), and 27.0% as low risk (

KW - Aspirin

KW - Chronic coronary syndrome

KW - Coronary artery disease

KW - Myocardial infarction

KW - Platelet inhibitors

KW - Rivaroxaban

U2 - 10.1093/eurheartj/ehab785

DO - 10.1093/eurheartj/ehab785

M3 - Journal article

C2 - 34871376

SN - 0195-668X

VL - 43

SP - 996

EP - 1004

JO - European Heart Journal

JF - European Heart Journal

IS - 10

ER -

Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score

Abstract

Keywords

Access to Document

Fingerprint

Cite this